2-(2'-amino-6'-chloropurin-9'-yl)-5-hydroxymethyl-3,4-O-isopropylidene-tetrahydrofuran | 63629-80-1

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2-(2'-amino-6'-chloropurin-9'-yl)-5-hydroxymethyl-3,4-O-isopropylidene-tetrahydrofuran
• 英文别名: 1-(2-amino-6-chloro-purin-9-yl)-O²,O³-isopropylidene-β-D-1-deoxy-ribofuranose；(2R,3S,4S,5R)-2-(2'-amino-6'-chloropurin-9'-yl)-5-hydroxymethyl-3,4-O-isopropylidene-tetrahydrofuran；[(3aR,4R,6R,6aR)-4-(2-amino-6-chloropurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol
• CAS: 63629-80-1
• 化学式: C₁₃H₁₆ClN₅O₄
• 分子量: 341.754
• InChiKey: ASUMUMWHOCKLBS-IOSLPCCCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  118
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-(2'-amino-6'-chloropurin-9'-yl)-5-hydroxymethyl-3,4-O-isopropylidene-tetrahydrofuran 在 氢氧化钾 、 potassium permanganate 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 2-(2'-amino-6'-chloropurin-9'-yl)-5-ethylcarboxyamide-3,4-O-isopropylidene-tetrahydrofuran
  参考文献：
  名称：

  Structure−Activity Relationships of 2,N⁶,5‘-Substituted Adenosine Derivatives with Potent Activity at the A_2B Adenosine Receptor

  摘要：

  2, N-6, and 5'-substituted adenosine derivatives were synthesized via alkylation of 2-oxypurine nucleosides leading to 2-arylalkylether derivatives. 2-(3-(Indolyl)ethyloxy)adenosine 17 was examined in both binding and cAMP assays and found to be a potent agonist of the human A(2B)AR. Simplification, altered connectivity, and mimicking of the indole ring of 17 failed to maintain A2BAR potency. Introduction of N-6-ethyl or N-6-guanidino substitution, shown to favor A2BAR potency, failed to enhance potency in the 2-( 3-( indolyl)ethyloxy) adenosine series. Indole 5 ''- or 6 ''-halo substitution was favored at the A(2B)AR, but a 5'-N-ethylcarboxyamide did not further enhance potency. 2-(3 ''-(6 ''-Bromoindolyl)ethyloxy)adenosine 28 displayed an A(2B)AR EC50 value of 128 nM, that is, more potent than the parent 17 (299 nM) and similar to 5'-N-ethylcarboxamidoadenosine (140 nM). Compound 28 was a full agonist at A(2B) and A(2A)ARs and a low efficacy partial agonist at A(1) and A(3)ARs. Thus, we have identified and optimized 2-(2-arylethyl) oxo moieties in AR agonists that enhance A(2B)AR potency and selectivity.

  DOI：

  10.1021/jm061278q
• 作为产物：
  描述：

  6-氯鸟嘌呤核苷 、 2,2-二甲氧基丙烷 在 对甲苯磺酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以50%的产率得到2-(2'-amino-6'-chloropurin-9'-yl)-5-hydroxymethyl-3,4-O-isopropylidene-tetrahydrofuran
  参考文献：
  名称：

  Structure−Activity Relationships of 2,N⁶,5‘-Substituted Adenosine Derivatives with Potent Activity at the A_2B Adenosine Receptor

  摘要：

  2, N-6, and 5'-substituted adenosine derivatives were synthesized via alkylation of 2-oxypurine nucleosides leading to 2-arylalkylether derivatives. 2-(3-(Indolyl)ethyloxy)adenosine 17 was examined in both binding and cAMP assays and found to be a potent agonist of the human A(2B)AR. Simplification, altered connectivity, and mimicking of the indole ring of 17 failed to maintain A2BAR potency. Introduction of N-6-ethyl or N-6-guanidino substitution, shown to favor A2BAR potency, failed to enhance potency in the 2-( 3-( indolyl)ethyloxy) adenosine series. Indole 5 ''- or 6 ''-halo substitution was favored at the A(2B)AR, but a 5'-N-ethylcarboxyamide did not further enhance potency. 2-(3 ''-(6 ''-Bromoindolyl)ethyloxy)adenosine 28 displayed an A(2B)AR EC50 value of 128 nM, that is, more potent than the parent 17 (299 nM) and similar to 5'-N-ethylcarboxamidoadenosine (140 nM). Compound 28 was a full agonist at A(2B) and A(2A)ARs and a low efficacy partial agonist at A(1) and A(3)ARs. Thus, we have identified and optimized 2-(2-arylethyl) oxo moieties in AR agonists that enhance A(2B)AR potency and selectivity.

  DOI：

  10.1021/jm061278q

文献信息

• [EN] A2 ADENOSINE RECEPTOR AGONISTS<br/>[FR] AGONISTES DES RÉCEPTEURS D'ADÉNOSINE A2
  申请人：US GOV HEALTH & HUMAN SERV

  公开号：WO2009006089A3

  公开（公告）日：2009-04-09
• [EN] RNA POLYMERASE INHIBITORS AND METHODS USING SAME<br/>[FR] INHIBITEURS D'ARN POLYMÉRASE ET PROCÉDÉS LES UTILISANT
  申请人：[en]ARBUTUS BIOPHARMA CORPORATION

  公开号：WO2023152709A1

  公开（公告）日：2023-08-17

  The present disclosure relates to compounds of formula (I) and compositions thereof, which are useful for the treatment, amelioration, or prevention of coronavirus infections. A1is selected from the group consisting of (II), (III) and (IV).
• Structure−Activity Relationships of 2,<i>N</i>⁶,5‘-Substituted Adenosine Derivatives with Potent Activity at the A_2B Adenosine Receptor
  作者：Hayamitsu Adachi、Krishnan K. Palaniappan、Andrei A. Ivanov、Nathaniel Bergman、Zhan-Guo Gao、Kenneth A. Jacobson

  DOI：10.1021/jm061278q

  日期：2007.4.1

  2, N-6, and 5'-substituted adenosine derivatives were synthesized via alkylation of 2-oxypurine nucleosides leading to 2-arylalkylether derivatives. 2-(3-(Indolyl)ethyloxy)adenosine 17 was examined in both binding and cAMP assays and found to be a potent agonist of the human A(2B)AR. Simplification, altered connectivity, and mimicking of the indole ring of 17 failed to maintain A2BAR potency. Introduction of N-6-ethyl or N-6-guanidino substitution, shown to favor A2BAR potency, failed to enhance potency in the 2-( 3-( indolyl)ethyloxy) adenosine series. Indole 5 ''- or 6 ''-halo substitution was favored at the A(2B)AR, but a 5'-N-ethylcarboxyamide did not further enhance potency. 2-(3 ''-(6 ''-Bromoindolyl)ethyloxy)adenosine 28 displayed an A(2B)AR EC50 value of 128 nM, that is, more potent than the parent 17 (299 nM) and similar to 5'-N-ethylcarboxamidoadenosine (140 nM). Compound 28 was a full agonist at A(2B) and A(2A)ARs and a low efficacy partial agonist at A(1) and A(3)ARs. Thus, we have identified and optimized 2-(2-arylethyl) oxo moieties in AR agonists that enhance A(2B)AR potency and selectivity.